Structure Therapeutics presents Phase 2b ACCESS obesity trial data for aleniglipron at ADA 2026

PUBT·04/27/2026 20:07:23

Listen to the news

Structure Therapeutics scheduled new Phase 2b ACCESS trial results for oral obesity drug candidate aleniglipron for presentation at American Diabetes Association 86th Scientific Sessions on June 5, 2026.
Planned presentation highlights meaningful weight reduction in people with obesity or overweight, supporting continued clinical development of an oral small-molecule GLP-1 option.
Separate Phase 2 ACCESS II data on safety, tolerability, and efficacy at higher doses will be presented on June 8, 2026.
Late-breaking posters on June 7, 2026 will outline work to improve gastrointestinal tolerability with a lower starting dose, alongside preclinical combination findings pairing aleniglipron with amylin candidate ACCG-2671 that showed additional weight loss versus single-agent treatment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Structure Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604271605PRIMZONEFULLFEED9707686) on April 27, 2026, and is solely responsible for the information contained therein.

FAQ

Fee Schedule Open Account Deposit & Withdrawal Trading

Terms & Conditions

Client Agreement Privacy Policy Data Disclaimer Security Tips

About Webull

About us Webull Promotions Contact information Announcements

Contact Number :+852 3852 8500

Monday 7:00 AM - Saturday 9:00 AM (HKT)

Service Email :service@webull.hk

Online Support: Monday - Friday: 9:00 - 16:00; 22:30 - 5:00 (HKT)

Business Cooperation :marketinghk@webull.hk

Risk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.

Language

English